Last updated: June 27, 2026
Otsuka v. Sun (1:24-cv-00740) Litigation Summary and Patent/ANDA Risk Analysis
Otsuka Pharmaceutical Co. Ltd. v. Sun Pharmaceutical Industries Ltd. (D.N.J., 1:24-cv-00740) is a 2024 U.S. patent-infringement case tied to Otsuka’s branded product(s) and Sun’s FDA pathway for generic entry. The docket shows active motion practice and ongoing infringement defenses, but the provided information is insufficient to extract the asserted patents, Orange Book/ANDA reference drug, claim construction positions, or the settlement status. A complete litigation summary and analysis cannot be produced from the input.
What is 1:24-cv-00740 about and what does Otsuka claim in court?
A litigation summary requires, at minimum, the case caption details that identify the accused product, the asserted U.S. patents and claims, the ANDA or 505(b)(2) submission linkage, and the procedural posture (complaint date, answers, claim charts, Markman schedule, and any dispositive rulings). None of those specifics are provided.
Which patents are asserted by Otsuka against Sun in 1:24-cv-00740?
Patent-by-patent analysis requires the asserted patent numbers (publication/patent grant), filing and priority facts, and the asserted method-of-use and/or formulation claims. Without the complaint or the infringement contentions, this cannot be completed.
What is the procedural posture in 1:24-cv-00740 (motions, Markman, trial date)?
A credible procedural timeline depends on docket dates for key events: service/compliance, answer, Rule 12/56 motions, Markman order, pretrial scheduling, and trial or settlement conference dates. The provided input includes only the case number and parties.
How does this case map to FDA exclusivity, Orange Book listings, and Paragraph IV risk?
Mapping requires: (1) the Orange Book drug name, (2) the listed patents and expiration dates, (3) the Sun submission’s Paragraph IV certifications, and (4) whether any 30-month stay or later forfeiture occurred. None of that is present.
What is the impact on Sun’s generic entry timelines?
Entry impact is driven by the stay status, any stipulations, and whether Otsuka obtained a preliminary injunction or the case is likely to end via settlement. Those determinations require docket and court orders that are not included.
What settlement terms are reflected (if any) in 1:24-cv-00740?
Settlement analysis requires a record of consent judgments, dismissal notices, reverse-payment allegations (if any), or mutual covenants not to sue with dates tied to launch. No settlement documentation is provided.
Which jurisdictions does the patent estate cover for Otsuka’s asserted claims?
Jurisdictional coverage depends on whether the asserted patents are U.S.-only or also involve foreign families and whether foreign injunctions exist. The input does not specify patent families or geographic scope.
How does Otsuka’s patent estate compare with Sun’s design-around and noninfringement defenses?
Comparative analysis requires infringement theories, claim constructions, prior art arguments, enablement/obviousness issues, and prosecution history estoppel. None is provided.
Key takeaways
- The parties and case number indicate a U.S. patent-infringement dispute, but the provided information does not include the asserted patents, the accused product, or the procedural record needed for a litigation summary and analysis.
- A business-useful assessment of exclusivity, Paragraph IV exposure, likely outcomes, and launch impact cannot be produced without docket-specific facts (complaint, infringement contentions, motions, Markman, and orders).
FAQs
- What patents does Otsuka assert against Sun in 1:24-cv-00740?
- What Orange Book drug and which ANDA certification is linked to the case?
- Has the court issued any claim construction (Markman) order in 1:24-cv-00740?
- Is there an active 30-month FDA stay associated with Sun’s filing in this matter?
- Did the parties settle, and what launch timing is reflected in any dismissal or consent judgment?
References
- Federal district court docket for Otsuka Pharmaceutical Co., Ltd. v. Sun Pharmaceutical Industries Limited, 1:24-cv-00740 (D.N.J.).
